Company performance
Add to research
Current Price
as of Apr 17, 2025$2.42
P/E Ratio
N/A
Market Cap
$721.13M
Description
Add to research
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
Metrics
Add to research
Overview
- HQVancouver, BC
- SectorHealth Technology
- IndustryBiotechnology
- TickerABCL
- Price$2.42+1.26%
Trading Information
- Market cap$721.13M
- Float75.03%
- Average Daily Volume (1m)4,112,549
- Average Daily Volume (3m)4,301,171
- EPS-$0.55
Company
- Revenue$28.83M
- Rev growth (1yr)-24.17%
- Net income-$162.86M
- Gross margin-236.42%
- EBITDA margin-755.27%
- EBITDA-$217.77M
- EV$275.03M
- EV/Revenue9.54
- P/EN/A
- P/S24.70
- P/B0.68
- Debt/Equity6.19
Documents
Add to research
SEC Filings
Factset Street Account
Earnings Calls
Factset